Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.

CD47-amyloid-β-CD74 signaling is a key driver of adaptive immunosuppression in sepsis, suppressing B cells and impairing ...

Data from the DIAN-TU-001 trial showed that Roche’s gantenerumab, an amyloid beta peptide inhibitor, reduced amyloid levels in the brain and improved some measures of Alzheimer’s proteins, but did not ...

Roche has reported preliminary results on its Alzheimer’s disease prospect trontinemab. | Roche has reported preliminary ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

Panelists discuss how amyloid-targeting therapies for Alzheimer disease represent a breakthrough drug class that works by ...

A new research paper was published in Aging (Aging-US) on March 29, 2025, as the cover of Volume 17, Issue 3, titled ...

A study identifies senolytic compounds that can inhibit specific brain enzymes associated with Alzheimer’s disease (AD) while ...

Alzheimer's disease, the leading cause of dementia, affects over 55 million people worldwide. The disease is characterized by the buildup of amyloid-beta plaques and tau protein tangles in the ...

Medically reviewed by Femi Aremu, PharmD Dementia is a loss of brain function that affects memory, thinking, judgment, behavior, and language. Alzheimer's disease is the most common type of dementia.

An illustration depicts cells in an Alzheimer’s-affected brain, with abnormal levels of beta amyloid protein clumping together to form plaques that collect between neurons and disrupt cell function.